(Aceclofenac + eperisone SR) is under clinical development by NVP Healthcare and currently in Phase III for Low Back Pain. According to GlobalData, Phase III drugs for Low Back Pain have a 12% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Aceclofenac + eperisone SR)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Aceclofenac + eperisone SR) overview

A fixed-dose combination of aceclofenac and eperisone SR is under development for the treatment of acute low back pain, muscle spasm and musculoskeletal disorder. The drug candidate is administered orally. Aceclofenac acts by targeting cyclooxygenase-2 (COX-2) enzyme. Eperisone acts by targeting alpha 1 adrenergic receptor, alpha 2 adrenergic receptor, muscarinic acetylcholine receptor (mAChR) and serotonin (5-HT) receptor. It is an incrementally modified drug (IMD).

NVP Healthcare overview

NVP Healthcare formerly Navipharm, develops novel pharmaceuticals products and microbiomes. NVP Healthcare is headquartered Suwon, Gyeonggi, South Korea.

For a complete picture of (Aceclofenac + eperisone SR)’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.